Dr. Reddy’s Laboratories announced on Monday the signing of a commercialisation deal for Australian pharma firm Hatchtech’s prescription head lice product Xeglyze Lotion.

Exclusive rights

“The exclusive rights for this product are applicable for the territories of the US, Canada, India, Russia and the CIS, Australia, New Zealand and Venezuela,” a release from the Hyderabad-based Dr. Reddy’s said.

Promius Pharma, a wholly-owned specialty firm of Dr. Reddy’s, will market the product in the US if the new drug application of Hatchtech gets the approval of the US Food and Drug Administration.

Under the agreement, Dr. Reddy’s will pay Hatchtech US $10 million upfront, up to $ 50 million based on pre commercialisation milestones and an undisclosed amount based on post commercialisation milestones, the release said.

Active drug substance

The active drug substance for Xeglyze lotion was developed in collaboration with Dr. Reddy’s Custom Pharmaceutical Services (CPS) business unit. In September last year, the Australian firm had announced positive results from its two pivotal Phase 3 clinical studies evaluating the lotion as a potential treatment for head lice infestation.

source: http://www.thehindu.com / The Hindu / Home> News> Cities> Hyderabad / by N. Ravi Kumar / Hyderabad – September 15th, 2015